London · Delayed Price · Currency is GBP · Price in GBX genedrive Earnings Call Transcripts
Fiscal Year 2026
-
Rapid pharmacogenetic testing solutions are driving revenue growth and adoption in the UK and internationally, with two CE-IVD certified products addressing critical clinical needs. Key milestones include NICE guidance and NHS England procurement in July 2027, international expansion, and a focus on recurring consumables revenue.
Fiscal Year 2025
-
Rapid pharmacogenetic tests for emergency care are gaining traction, with FY25 revenue reaching GBP 1 million and strong clinical adoption in the U.K. and abroad. Regulatory progress, pilot programs, and new funding position the company for further growth, though additional capital is needed.
Fiscal Year 2024
-
Revenue grew to GBP 500,000 as adoption of two innovative pharmacogenetic tests increased, though losses widened due to R&D and scaling costs. Regulatory progress, strong clinical endorsements, and expanding international traction position the company for future growth.